HER2/neu and α-Methylacyl Coemzyme A Racemase Overexpression in Prostatic Cancer as Indicators for Prognosis

Main Article Content

Hadi M. AL-Mosawi

Abstract

prostatic cancer is a malignant neoplasm characterized by elevated level 7-8 folds in both mRNA  and protein levels during tumorigenesis of the prostate. Also, HER2/neu expression  could be detected in  prostatic intraepithelial neoplasia (PIN) ,It affects androgen receptor function  and the progression of prostatic cancer and thedetermination of Association between HER2/neu and α-methylacyl coemzyme A racemase (AMACR) overexpressions in prostatic cancer as prognostic factors. This study  included 50 patients aged from 50- < 70 years and 10 healthy men as control group matched with patient group ages. Then,  paraffin-embedding procedure was prepared on   tissues biopsy and then, hematoxylin and eosin staining (H. and E. staining) procedure was done . Finally, immunohistochemical procedure is done on both control cases and prostate cancer blocks. This immunohistochemical procedure detects her2/neu  and AMACR overexpression according to  DAKO protocol scoring system. The study showed that there is no significant difference in ages (P >0.05) between prostatic cancer patient and control group (68.46±6.26 years , 62.79±8.68 years)  respectively and the prostatic cancer is more prevalence in ages >69 years old which represent 56% of cases.


 Also, the overexpression of AMACR  represent  weak positive  (46%), moderate positive   (34%), strong (20%) overexpressions. While, the overexpression of HER2/neu  gives  weak positive   (60%),  strong positive (40%) and the death occurred to 50% of prostatic cancer patient that have strong positive HER2/neu overexpression.  Those whose  ages are more than 69 years old who have liability for prostatic cancer . Immunohistochemical overexpressions of  α-methylacyl coemzyme A racemase enzyme and HER2/neu have prognostic marker for prostatic cancer .

Article Details

How to Cite
[1]
“HER2/neu and α-Methylacyl Coemzyme A Racemase Overexpression in Prostatic Cancer as Indicators for Prognosis”, JUBPAS, vol. 26, no. 1, pp. 261–271, Dec. 2017, Accessed: Mar. 28, 2024. [Online]. Available: https://journalofbabylon.com/index.php/JUBPAS/article/view/399
Section
Articles

How to Cite

[1]
“HER2/neu and α-Methylacyl Coemzyme A Racemase Overexpression in Prostatic Cancer as Indicators for Prognosis”, JUBPAS, vol. 26, no. 1, pp. 261–271, Dec. 2017, Accessed: Mar. 28, 2024. [Online]. Available: https://journalofbabylon.com/index.php/JUBPAS/article/view/399

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>